Switch From Etravirine to Doravirine as a Part of Antiretroviral Combination - Trial NCT06155019
Access comprehensive clinical trial information for NCT06155019 through Pure Global AI's free database. This phase not specified trial is sponsored by Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida and is currently Not yet recruiting. The study focuses on HIV Infections. Target enrollment is 120 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
Timeline & Enrollment
N/A
Dec 15, 2023
Jun 15, 2024
Primary Outcome
Measure the virological efficacy at week 48 a doravirine-containing ART to assess the effectiveness of the switch to maintain the virological success to W48
Summary
The main objective of the SWEED study is to determine whether doravirine containing ART is
 able to maintain viral suppression at W48 in HIV-1 infected people living with HIV (PLWH)
 receiving etravirine containing ART:
 
 - An ARV strategy containing doravirine as a replacement for etravirine can maintain
 virological suppression in participants with controlled viral replication under ARV
 treatment containing etravirine, with a virological success rate 90%
 
 - This strategy can maintain virological suppression even in the event of NNRTI resistance
 mutations acquired in the past
 
 - This strategy is well tolerated
 
 - The emergence of resistance to NNRTIs is uncommon in the event of virological failure
 under the ARV regimen containing doravirine
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06155019
Non-Device Trial